Medical Care Technologies Inc. (OTC PINK:MDCE) Advances Skin Cancer Prevention with AI Mole Tracking System
Rhea-AI Summary
Medical Care Technologies (OTC PINK:MDCE) has announced the development of an AI-driven Mole Tracking System for early skin cancer detection. The innovative system utilizes full-body lesion indexing, 3D body-mapping algorithms, and temporal skin-change detection to create comprehensive dermatological profiles.
The technology aims to reduce dependence on invasive biopsies and expensive clinic visits by providing a consumer-facing, mobile-accessible solution. The system will be integrated into MDCE's beta app, scheduled for launch in 2026. The company is targeting the global dermatology diagnostics market, which currently exceeds $15 billion annually.
Positive
- Targeting $15 billion global dermatology diagnostics market with growth potential
- Innovative AI technology reduces need for invasive biopsies and costly clinic visits
- Mobile-accessible solution expands market reach to consumers
Negative
- Beta app launch not until 2026, indicating long time to market
- Faces regulatory approval hurdles and development timeline uncertainties
- Operating in highly competitive medical technology market
News Market Reaction – MDCE
In the Sep 4 session, MDCE declined 25.00%, reflecting a significant negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
MESA, ARIZONA / ACCESS Newswire / September 4, 2025 / Medical Care Technologies Inc. (OTC PINK: MDCE) is proud to announce the development of its AI-driven Mole Tracking System, a breakthrough dermatological monitoring tool for early skin cancer detection.
The system uses full-body lesion indexing, 3D body-mapping algorithms, and temporal skin-change detection to create longitudinal dermatological profiles for patients. This approach enables early identification of melanoma and other high-risk conditions, reducing reliance on invasive biopsies and costly clinic visits.
The global dermatology diagnostics market exceeds
"Skin cancer remains one of the most preventable yet deadly cancers when detected late," said CEO Marshall Perkins III. "Our technology empowers individuals and providers with AI-driven, real-time insights that can save lives."
The AI Mole Tracking platform is scheduled for inclusion in MDCE's beta app launch in 2026.
For more information visit: https://medicalcaretechnologies.com
Safe Harbor Statement:
This press release contains forward-looking statements within the meaning of federal securities laws. Actual results may differ materially due to risks and uncertainties, including market conditions, regulatory approvals, and product development timelines. Medical Care Technologies Inc. undertakes no obligation to update these statements except as required by law.
Contact:
Investor Relations
Medical Care Technologies Inc.
info@infiniteauctions.com
Website: www.mdcestock.com
SOURCE: Medical Care Technologies Inc. (OTC PINK:MDCE)
View the original press release on ACCESS Newswire